ArticleBMC medical informatics and decision making2025
Development and validation of machine learning classifiers for predicting treatment-needed retinopathy of prematurity.
Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to design and evaluate various supervised machine-learning models for identifying premature infants who require treatment based on demographic data and clinical findings from screening examinations.
methodsWe conducted a retrospective review of medical records for infants screened for retinopathy of prematurity (ROP) at our clinic over the past decade. We extracted demographic and clinical data, including eleven features: sex, maternal education, paternal education, birth weight, gestational age, ROP stage, zone of retinal involvement, age at examination, weight at examination, and CPR. We developed and assessed several classifiers: logistic regression (LR), decision tree (DT), support vector machine (SVM), naïve Bayes (NB), K-nearest neighbors (KNN), XGBoost, artificial neural networks (ANN), and random forest (RF). The target variable was defined as whether the neonate received any treatment during the follow-up period.
resultsOur analysis included data from 9,692 infants. Among the machine learning models evaluated, the XGBoost and ANN models achieved the highest accuracy at 96%. In terms of sensitivity (recall), the NB model exhibited the lowest false negative rate, indicating the highest sensitivity (0.99). In the context of premature neonates, accurately diagnosing those who require treatment is crucial. Therefore, from a clinical perspective, prioritizing a model with the lowest false negative rate may be more beneficial than selecting one based solely on the highest accuracy.
conclusionWhile AI can enhance decision-making processes by providing real-time risk assessments, these tools must be used to augment-not replace-clinical judgment. Clinicians must remain involved in interpreting model outputs and making final treatment decisions based on a holistic understanding of each patient's unique circumstances. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.